top of page
Nine africans partners are involved in this project such are Benin, Cameroon, Democratic Republic of Congo, Ethiopia, Guinea, Mali, Nigeria, Rwanda and Senegal.
In some African partners (Benin and Rwanda) with advanced molecular laboratories, the ‘Deeplex’ assay, a novel multiplex deep sequencing-based drug resistance diagnostic platform that simultaneously provides sequence information of genes that confer resistance to severals key anti-TB drugs has been implemented.
Welcome On Diama Project
(Diagnosis of Multidrug resistant tuberculosis in Africa) website
The DIAMA (DIAgnostics for Multidrug resistant tuberculosis in Africa) study aims to address current gaps in the diagnosis and management of patients with Multi-Drug-Resistant (MDR) tuberculosis (TB).
Who We are?
A network of West, Central, East African as well as European instititions
To evaluate and implement rapid and accurate molecular tests for the management of drug resistant tuberculosis to replace the current dependency on culture.
To live in a world where drug resistant tuberculosis is managed without culture
Latest News & Events
Subscribe To Our Newsletter
For The Latest Updates, News and Events
bottom of page